Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage.
It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.
Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | 0.36 Increased by +1.90 K% | 0.31 Increased by +16.13% |
| May 8, 24 | 0.26 Decreased by -10.34% | 0.38 Decreased by -31.58% |
| Feb 27, 24 | 0.89 Increased by +106.98% | 0.55 Increased by +61.82% |
| Nov 8, 23 | 0.24 Increased by +700.00% | 0.08 Increased by +200.00% |
| Aug 8, 23 | -0.02 Decreased by -114.29% | -0.23 Increased by +91.30% |
| May 9, 23 | 0.29 Decreased by -32.56% | 0.17 Increased by +70.59% |
| Feb 28, 23 | 0.43 Increased by +975.00% | 0.68 Decreased by -36.76% |
| Nov 8, 22 | 0.03 Decreased by -92.50% | 0.36 Decreased by -91.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 175.69 M Increased by +14.17% | 38.50 M Increased by +340.97% | Increased by +21.91% Increased by +311.06% |
| Jun 30, 24 | 168.32 M Increased by +24.17% | 19.92 M Increased by +2.50 K% | Increased by +11.83% Increased by +2.03 K% |
| Mar 31, 24 | 143.64 M Decreased by -6.58% | 124.00 K Decreased by -99.27% | Increased by +0.09% Decreased by -99.22% |
| Dec 31, 23 | 164.31 M Decreased by -1.80% | 1.18 M Decreased by -95.39% | Increased by +0.72% Decreased by -95.30% |
| Sep 30, 23 | 153.88 M Decreased by -13.24% | -15.98 M Decreased by -1.01 K% | Decreased by -10.38% Decreased by -1.15 K% |
| Jun 30, 23 | 135.56 M Decreased by -20.28% | -831.00 K Decreased by -110.57% | Decreased by -0.61% Decreased by -113.25% |
| Mar 31, 23 | 153.76 M Decreased by -3.32% | 16.95 M Increased by +594.02% | Increased by +11.02% Increased by +617.88% |
| Dec 31, 22 | 167.33 M Increased by +5.20% | 25.48 M Increased by +943.45% | Increased by +15.23% Increased by +891.83% |